An Antibody Engineering Service against tumor necrosis factor-alpha (TNF-α), like infliximab, is an attractive therapeutic approach to treat ocular surface diseases. TNF-α is a pleiotropic cytokine with an essential contribution to the pathogenesis of inflammation angiogenesis and collagenolysis. An individual intraperitoneal dose[…]
Read MoreThe serious acute respiratory syndrome covid 2 is the etiological agent of the covid induced disease 19 that emerged in china in late 2019 and caused a global pandemic. SARS-CoV-2 belongs to the subgenus Sarbecovirus together with SARS-CoV that emerged in 2002[…]
Read MoreScientists are considering recombinant antibodies as the next step in antibody technology. Recombinant monoclonal antibodies have been rising in significant roles in the field of researching and constructing medical compounds and therapies. Today’s medicine benefits from many key factors that make recombinant[…]
Read MoreUnderstanding the immune memory and tracking variant immunity to the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is vital for improving the continuous diagnosis and enhancing treatment in form of vaccines for any future outbreaks. Monitoring the variant immunity for SARS-CoV-2 spike[…]
Read MoreThe very first monoclonal antibody approved by the U.S. FDA (Food and Drug Administration) in 1997 ushered a new era in therapeutic applications for patients. A clinical breakthrough was acknowledged in the 1990s when there was the successful development of a humanized[…]
Read MoreThe progress in engineering and clinical development has been remarkable in the development of Therapeutic Antibody for 40 years, with the work done by Kohler and Milstein. The US FDA has led approval to the 21 antibodies for cancer immunotherapy. The approved[…]
Read MorePhage display antibody library technology has played an important role in the remarkable progress of discovering and optimizing antibodies for diverse applications, specifically monoclonal antibody drugs. The technology was firstly introduced by George smith and applied by john McCafferty. Here we compare[…]
Read MoreTreatment of diseases arose with the concept of antibodies back in the 1890s, by Emil Adolf von Behring. In the further 1960s, there were structural characteristics describers, forward marking discovery of production methods of Monoclonal Antibodies (mAbs). The first mAb, muromonab-CD3, was[…]
Read MoreGolimumab has been principally targeting and neutralizing TNF proving itself as a valuable human anti-tumor necrosis factor (TNF) monoclonal antibody, actively preventing inflammation and destruction of cartilage and bone. Golimumab, monoclonal antibody production, is largely represented by the biological community. 1. Sequential[…]
Read MoreChimeric and humanized antibodies are monoclonal antibodies that are non-human and are set into production by mice or rodents under specific laboratory conditions. Chimeric antibody usually tracks down and illuminize the tumour regions, whereas the humanized antibodies antigenic region is derived from[…]
Read More